ISPOR - PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM

PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM

Abstract

Authors

J.P.D.S.N. Lima P. Marinheiro G. Bernardino

Full Text Cite This Article

Back to Volume 19, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now